During the pandemic FDA and other regulatory bodies around the world has worked quite efficiently and we saw more than 50 new drug approvals in the US in 2020. We are expecting to see a significant number of approvals in 2021 with several of those coming from BB Biotech´s portfolio companies.
BB Biotech invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. It focuses on biotech companies whose products address areas of significant unmet medical needs and thus have above-average sales and profit-growth potential.
The renowned Board of Directors of BB Biotech AG has many years of industrial and scientific experience. A team of proven biotech specialists from Bellevue Asset Management AG takes care of investments in the most attractive biotech companies.
